European Union: General Data Protection Regulation: The Impact On Clinical Trials And Data Subjects

Richard Dickinson, Jackie Mulryne and Zoe Walkinshaw, Arnold & Porter Kaye Scholer LLP, consider how the GDPR will impact clinical trials

The EU rules on data protection seek to protect individuals by placing restrictions on the processing (collecting, storing or using) of their personal data. Under the new General Data Protection Regulation 2016/679/EU ("GDPR"), which will apply throughout the EU from May 25, 2018, these rules have been strengthened: data subjects have new rights to help ensure their data are processed securely and with adequate protections, and clearer responsibilities and obligations are placed on companies using such data.

However, these strengthened rights do not necessarily fit neatly with other sector specific legislation where large quantities of data are collected and processed. In particular, the GDPR raises some important questions for clinical trials, one of the fundamental aspects of which is the collection and analysis of sensitive personal data. Importantly, there are no transitional rules governing how data currently held and being collected will be dealt with once the GDPR becomes applicable, although guidance is expected before May 2018 to clarify how some of these provisions will operate.

While the implications for clinical trials are huge, this post focuses on the changes that affect the collection of data from data subjects, and their rights under the GDPR.

Which Data are covered?

Health data, which are usually at issue in clinical trials, are classed as sensitive personal data, and under both the current legislation and the GDPR, are subject to tighter conditions for processing compared to other types of personal data (e.g. contact details). However, the GDPR has widened the data that are classed as sensitive personal data, to specifically include biometric and genetic data, and introduces new compliance requirements for such data.

An important question for clinical trials is whether pseudonymized data are covered by the legislation, meaning data where a key is held so it is (theoretically) possible to re-identify patients using "anonymous" patient codes. Under the GDPR, pseudonymized data will be a form of personal data and will have to be protected accordingly. In reality, confidentiality and data security provisions are applied to such data in the context of clinical trials in any event. However, this clarification in the GDPR will mean additional steps may have to be taken with respect to such data.

How can Subjects Consent to Processing of their Data?

Although not the only legal basis for processing sensitive personal data under the GDPR, obtaining informed consent from clinical trial subjects before they participate in the trial is required by the Clinical Trials Directive 2001/20/EC and the new Clinical Trials Regulation 536/2014/EU, and is also best practice under the GDPR.

Consent must be explicit, unambiguous, and freely given. It must be specific to each procedure, and only used for those purposes set out in the consent form. The GDPR also introduces stricter requirements including:

  • Enabling individuals to provide consent for different parts of collection and processing (granular consent)
  • Keeping records to show what individuals have consented to, what they were told, and when and how they consented
  • Making consent easy to withdraw, at which point the relevant processing activities will need to be reconsidered
  • Stricter consent requirements for minors or incapacitated data subjects

Under the GDPR, certain information must be provided to individuals before their personal data are obtained, such as the identity and contact details of the data controller (i.e. the sponsor), the contact details of the data protection officer, the purposes and legal basis for processing, the recipients of the data, how long the data will be stored, and the rights individuals have under the legislation. This will also have to be combined with the information required to be provided about the trial, as set out in the Clinical Trials Directive and Regulation, and will likely lead to very long and detailed consent forms – at a time when ethics committees are seeking to simplify such forms.

Under the GDPR, consent does not provide a legal basis for processing where there is a "clear imbalance" between the data subject and the controller, meaning it is unlikely that consent was freely given. What this means in practice, and its implications for patients and pharmaceutical companies during clinical trials, will need to be clarified.

Further, the status of consents validly provided under the current legislation is still unclear. As the requirements for consent are stricter under the GDPR, and as there are no transitional provisions covering how data currently collected will be dealt with – or specific guidance in relation to clinical trials – current consent forms should be reviewed and updated. However, it is unclear whether sponsors will need to obtain new consents from patients already involved in trials. Clarification on this issue would be welcome.

What New Rights do Clinical Trial Subjects have?

The new rights to erasure of personal data (the "right to be forgotten") and to data portability could have far-reaching implications for clinical trials if not managed appropriately – by sponsors and regulators.

First, in accordance with the erasure right, the data controller (i.e. the sponsor) will have to delete personal data, and take all reasonable steps to tell third parties to do the same, if the data subject requests it. There are exceptions to this, such as where processing is necessary for reasons of public interest in the area of public health, or scientific or historical research purposes. While carving out these exemptions seems to be seeking to reconcile the competing values of privacy of patients and innovation by companies, further guidance on their scope is required.

Secondly, the right of data portability means that clinical trial subjects have the right to receive their personal data in a commonly used and machine-readable format, and transmit such data to another organization. This is not an unfettered right; there is the qualification that data portability should not adversely affect the rights and freedoms of others (which in this case, might include intellectual property or trade secrets of the sponsor), but businesses are expected to take steps to comply with a data portability request if received.

Again, the extent to which patients already enrolled in trials also benefit from these rights will hopefully be clarified before May 2018.

What New Compliance Measures do Companies Need to Consider?

As clinical trials involve the processing of sensitive personal data, the sponsor will need to carry out a data protection impact assessment, likely both for trials commenced after May 25, 2018, and for trials that are ongoing and data that are being processed at that date. This assessment must set out:

  • A description of the processing operations and the purposes of processing
  • An assessment of the necessity and proportionality of the processing
  • An assessment of the risks to the rights and freedoms of clinical trial subjects
  • The measures used to address those risks

Controller and processor organizations involved with the running of clinical trials (e.g. sponsors, CROs and investigators) will also likely need to appoint a data protection officer. It would be their responsibility to inform and advise their organization about its obligations under the GDPR, monitor compliance with the GDPR, provide advice where requested, and act as a point of contact for the relevant regulator. In addition, all organizations involved with clinical trials should maintain documentation evidencing any consents obtained and the steps taken to comply with the GDPR. Such documents will likely need to be contained in the trial master file, with other trial-related information, to show compliance with applicable laws.

Which Company is Responsible for Compliance?

Under the current rules, the data controller (i.e. sponsor) has full responsibility for compliance. This is changing under the GDPR, which allows for the appointment of joint data controllers, and also imposes obligations on data processors (i.e. CROs, investigators or statisticians). The Clinical Trials Regulation also provides the ability to have co-sponsors, and non-commercial sponsors, all of who will have obligations under the Clinical Trials Regulation and the GDPR.

What are the Sanctions for Non-compliance?

Penalties under the GDPR are substantial: national regulators will have the power to impose fines of up to €20 million or 4 percent annual global turnover, whichever is the higher. It is not yet clear how liability or any fines in the case of a data breach would be divided up between data controllers and data processors. However, it is clear that all organizations should consider their processes in light of the GDPR, and understand the remit of their compliance responsibilities, particularly for trials and data processing that have already started.

Originally published by Clinical Trails Arena.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Wilson Elser Moskowitz Edelman & Dicker LLP
Klein Moynihan Turco LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Wilson Elser Moskowitz Edelman & Dicker LLP
Klein Moynihan Turco LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions